Effect of Mirabegron on Intraocular Pressure in Patients with Glaucoma

Effect of Mirabegron on Intraocular Pressure in Patients with Glaucoma

Objective:Assessment of the effects of mirabegron treatment used for overactive bladder (OAB) symptoms in glaucoma patients on intraocular structures.Materials and Methods:One hundred-twenty six female glaucoma patients, who received mirabegron treatment for OAB symptoms between January 2017 and Jan...

Full description

Saved in:

Bibliographic Details
Main Authors:	Emine Şeker Ün, Sıtkı Ün
Format:	Article
Language:	English
Published:	Galenos Publishing House 2020-06-01
Series:	Journal of Urological Surgery
Subjects:	mirabegron glaucoma overactive bladder
Online Access:	http://jurolsurgery.org/archives/archive-detail/article-preview/effect-of-mirabegron-on-ntraocular-pressure-in-pat/38524
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Acupuncture combined with mirabegron is efficacious for the treatment of overactive bladder: a prospective randomized controlled trial
by: Deng Xiaolin, et al.
Published: (2025-07-01)

How to choose appropriate medication for overactive bladder: Findings from the largest integrated clinical trial database analysis of mirabegron studies
by: Hann-Chorng Kuo
Published: (2022-01-01)

Mirabegron in the Management of Overactive Bladder Syndrome in Ghazi Al-Hariri Hospital
by: Hiba H. Razaq, et al.
Published: (2025-04-01)

Does Mirabegron the β3 Agonist Frequently Used in the Treatment of Overactive Bladder Really Affect the Respiratory System Negatively ? A Prospective Study
by: Şenol Adanur, et al.
Published: (2024-12-01)

An open-label, randomized, post-authorization study of mirabegron in Chinese participants with overactive bladder
by: Zhipeng Zhang, et al.
Published: (2025-01-01)

Comparison Of Outcome And Side Effects Profile Of Treatment Of Overactive Bladder With Different Classes Of Drugs
by: Nazish Sarfraz, et al.
Published: (2023-12-01)

Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder
by: Cheng-Ling Lee, et al.
Published: (2020-01-01)

Is the Addition of CO<sub>2</sub> Laser to β3-Adrenoceptor Agonist Mirabegron Effective in the Management of Overactive Bladder? Results of a Randomized Controlled Trial
by: Konstantinos Kypriotis, et al.
Published: (2025-06-01)

Multi-center, prospective, non-interventional, observational study on the efficacy and safety of Mirabek® in adult patients with overactive bladder
by: Jee Soo Park, et al.
Published: (2025-01-01)

Treating overactive bladder symptoms after transurethral prostatic surgery for benign prostatic hyperplasia – Which medication to choose?
by: Cheng-Ling Lee, et al.
Published: (2023-01-01)

Effect of β3-adrenergic receptor agonists on [18F] fluorodeoxyglucose uptake in brown adipose tissues in positron emission tomography images of elderly patients
by: John Kenneth V. Gacula, et al.
Published: (2025-08-01)

Effectiveness of Solifenacin versus Mirabegron in the Treatment of Overactive Bladder: A Prospective Cohort Study
by: Shyamali Dutta, et al.
Published: (2025-07-01)

Designing a sustained-release solid oral formulation for overactive bladder treatment: a quality by design approach
by: Neeraj Sharma, et al.
Published: (2025-02-01)

Eco-friendly spectrophotometric quantification of the potential combination of mirabegron and tamsulosin
by: Omar M El-Abassy, et al.
Published: (2025-06-01)

Green HPLC technique development for the simultaneous determination of the potential combination of Mirabegron and Tamsulosin
by: Eman A. Bahgat, et al.
Published: (2025-02-01)

Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients
by: Yuh-Chen Kuo, et al.
Published: (2023-01-01)

Efficacy and Safety of Mirabegron Compared to Solifenacin in Treatment of Non-neurogenic Overactive Bladder in Children: A Randomized Controlled Trial
by: Islam Mansour, et al.
Published: (2025-03-01)

Two birds with one stone: sustainable smart spectrophotometric methods for concurrent determination of silodosin and mirabegron: application to dosage forms and greenness assessment
by: Khalid M. Badr El-Din, et al.
Published: (2025-03-01)

The efficacy and safety of mirabegron and α-adrenergic receptor antagonist in the treatment of distal ureteral stones: a systematic review and meta-analysis
by: Yicheng Guo, et al.
Published: (2025-03-01)

Cutting-edge assays for mirabegron and tadalafil combo therapy for benign prostatic hyperplasia; insilico kinetics approach; multi trait sustainability assessment
by: Sara I. Aboras, et al.
Published: (2025-05-01)

Prevalence and Prognosis of Glaucoma/Elevated Intraocular Pressure in Patients with Uveitis
by: Mine Esen Barış, et al.
Published: (2025-08-01)

Sustainable UV approaches backed by one step extraction procedure for quantifying the newly released mirabegron and silodosin mixture in urine
by: Ahmed R. Mohamed, et al.
Published: (2025-08-01)

Mirabegron nighttime versus daytime dosing for women with overactive bladder syndrome: a randomized controlled trial
by: Sheng-Mou Hsiao
Published: (2025-08-01)

Influence of Phacoemulsification on Intraocular Pressure in Patients with Glaucoma
by: G. V. Voronin, et al.
Published: (2023-12-01)

Does Anticholinergic Burden Influence Therapeutic Success in Patients with Treatment-naïve Overactive Bladder?
by: João Oliveira, et al.
Published: (2025-09-01)

The impact of intraocular pressure fluctuations on the progression of glaucoma and associated factors
by: Tong Liu, et al.
Published: (2025-05-01)

Ahmed glaucoma valve implantation in a case of volatile intraocular pressure and preoperative hypotony
by: Blake Katsev, et al.
Published: (2025-06-01)

Efficacy and Tolerability of Solifenacin Fumarate with Overactive Bladder Patients: A Multicenter Observational Study
by: Jae Hun Shim, et al.
Published: (2021-04-01)

Association between overactive bladder and female sexual frequency: a cross-sectional analysis of the National Health and nutrition examination survey data
by: Bo Zhang, et al.
Published: (2025-02-01)

Anterior segment morphometric changes and intraocular pressure lowering after phacoemulsification with intraocular lens implantation for the prevention of pseudoexfoliative glaucoma in patients with pseudoexfoliation syndrome
by: V.O. Melnyk, et al.
Published: (2024-12-01)

Prevalence, impact on quality of life, and predictive factors of coexistence of overactive bladder and underactive bladder in men
by: Noritoshi Sekido, et al.
Published: (2025-07-01)

Outcomes of Sacral Neuromodulation and Intradetrusor Onabotulinum Toxin in the Management of Stroke Associated Urinary Incontinence
by: Tyler Trump, et al.
Published: (2025-03-01)

LOWER URINARY TRACT DYSFUNCTION IN PATIENTS WITH CHRONIC PYELONEPHRITIS
by: V. B. Berdichevskyy
Published: (2014-12-01)

The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis
by: Yuan-Hong Jiang, et al.
Published: (2023-01-01)

Semiology and clinical development of cystopathy in patients with type 2 diabetes mellitus
by: Igor Valentinovich Kuz'min, et al.
Published: (2013-06-01)

Clinical associations for the development of malignant glaucoma following intraocular surgery
by: Shantha Balekudaru, et al.
Published: (2025-03-01)

Melatonin in Glaucoma: Integrative Mechanisms of Intraocular Pressure Control and Neuroprotection
by: Xinyu Hou, et al.
Published: (2025-05-01)

The Effects of Lens Extraction Surgery on Intraocular Pressure and Anterior Segment Parameters in Primary Angle-Closure Glaucoma
by: Serdar Bayraktar, et al.
Published: (2024-02-01)

Intraocular Pressure Monitoring System for Glaucoma Patients Using IoT and Machine Learning
by: Sivamani Chinnaswamy, et al.
Published: (2024-01-01)

THE EFFECT OF INTRAVESICAL ONABOTULINUM TOXIN A TREATMENT ON QUALITY OF LIFE IN PATIENTS WITH OVERACTIVE BLADDER
by: Tuğçe Arslanoğlu, et al.
Published: (2023-03-01)